{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:42:50Z","timestamp":1793720570888,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7232145"],"award-info":[{"award-number":["No. 7232145"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7232145"],"award-info":[{"award-number":["No. 7232145"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7232145"],"award-info":[{"award-number":["No. 7232145"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7232145"],"award-info":[{"award-number":["No. 7232145"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7232145"],"award-info":[{"award-number":["No. 7232145"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7232145"],"award-info":[{"award-number":["No. 7232145"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7232145"],"award-info":[{"award-number":["No. 7232145"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7232145"],"award-info":[{"award-number":["No. 7232145"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7232145"],"award-info":[{"award-number":["No. 7232145"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03600-0","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:36:50Z","timestamp":1751431010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-interferon-\u03b1 antibodies associate with disease activity and prognosis in anti-MDA5-positive dermatomyositis"],"prefix":"10.1186","volume":"27","author":[{"given":"Chao","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"3600_CR1","doi-asserted-by":"crossref","unstructured":"Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78(4).","DOI":"10.1016\/j.jaad.2017.12.010"},{"key":"3600_CR2","doi-asserted-by":"crossref","unstructured":"Bay P, de Chambrun MP, Rothstein V, Mahevas M, De Prost N, Roux A et al. Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease. J Autoimmun. 2022;133.","DOI":"10.1016\/j.jaut.2022.102941"},{"key":"3600_CR3","doi-asserted-by":"crossref","unstructured":"Vuillard C, Pineton de Chambrun M, de Prost N, Gu\u00e9rin C, Schmidt M, Dargent A et al. Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study. Ann Intensive Care. 2018;8(1).","DOI":"10.1186\/s13613-018-0433-3"},{"key":"3600_CR4","doi-asserted-by":"crossref","unstructured":"So J, So H, Wong VT, Ho R, Wu TY, Wong PC et al. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. Rheumatology (Oxford). 2022;61(11).","DOI":"10.1093\/rheumatology\/keac094"},{"key":"3600_CR5","doi-asserted-by":"crossref","unstructured":"Horai Y, Koga T, Fujikawa K, Takatani A, Nishino A, Nakashima Y et al. Serum interferon-\u03b1 is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod Rheumatol. 2015;25(1).","DOI":"10.3109\/14397595.2014.900843"},{"key":"3600_CR6","doi-asserted-by":"crossref","unstructured":"Cassius C, Amode R, Delord M, Battistella M, Poirot J, How-Kit A et al. MDA5(+) dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN-\u03ba transcript. J Invest Dermatol. 2020;140(6).","DOI":"10.1016\/j.jid.2019.10.020"},{"key":"3600_CR7","doi-asserted-by":"crossref","unstructured":"Ye Y, Chen Z, Jiang S, Jia F, Li T, Lu X et al. Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5\u2009+\u2009dermatomyositis with therapeutic implications. Nat Commun. 2022;13(1).","DOI":"10.1038\/s41467-022-34145-4"},{"key":"3600_CR8","doi-asserted-by":"crossref","unstructured":"Qian J, Li R, Chen Z, Cao Z, Lu L, Fu Q. Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients. Front Immunol. 2023;14.","DOI":"10.3389\/fimmu.2023.1151695"},{"key":"3600_CR9","doi-asserted-by":"crossref","unstructured":"Postal M, Vivaldo JF, Fernandez-Ruiz R, Paredes JL, Appenzeller S, Niewold TB. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol. 2020;67.","DOI":"10.1016\/j.coi.2020.10.014"},{"key":"3600_CR10","doi-asserted-by":"crossref","unstructured":"Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis. 2023;82(8).","DOI":"10.1136\/ard-2022-223741"},{"key":"3600_CR11","doi-asserted-by":"crossref","unstructured":"Gupta S, Tatouli IP, Rosen LB, Hasni S, Alevizos I, Manna ZG et al. Distinct functions of autoantibodies against interferon in systemic lupus erythematosus: a comprehensive analysis of anticytokine autoantibodies in common rheumatic diseases. Arthritis Rheumatol. 2016;68(7).","DOI":"10.1002\/art.39607"},{"key":"3600_CR12","doi-asserted-by":"crossref","unstructured":"Harris BD, Kuruganti S, Deshpande A, Goepfert PA, Chatham WW, Walter MR. Characterization of type-I IFN subtype autoantibodies and activity in SLE serum and urine. Lupus. 2020;29(9).","DOI":"10.1177\/0961203320935976"},{"key":"3600_CR13","doi-asserted-by":"crossref","unstructured":"Slavikova M, Schmeisser H, Kontsekova E, Mateicka F, Borecky L, Kontsek P. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia. J Interferon Cytokine Res. 2003;23(3).","DOI":"10.1089\/107999003321532475"},{"key":"3600_CR14","doi-asserted-by":"crossref","unstructured":"Mathian A, Breillat P, Dorgham K, Bastard P, Charre C, Lhote R et al. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-\u03b1. Ann Rheum Dis. 2022;81(12).","DOI":"10.1136\/ard-2022-222549"},{"key":"3600_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1073\/pnas.2200413119","volume":"119","author":"J Manry","year":"2022","unstructured":"Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci U S A. 2022;119:21.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3600_CR16","doi-asserted-by":"crossref","unstructured":"Quiros-Roldan E, Sottini A, Signorini SG, Serana F, Tiecco G, Imberti L. Autoantibodies to interferons in infectious diseases. Viruses. 2023;15(5).","DOI":"10.3390\/v15051215"},{"key":"3600_CR17","doi-asserted-by":"crossref","unstructured":"Nishina N, Sato S, Masui K, Gono T, Kuwana M. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open. 2020;6(2).","DOI":"10.1136\/rmdopen-2020-001202"},{"key":"3600_CR18","doi-asserted-by":"crossref","unstructured":"So H, So J, Lam TT, Wong VT, Ho R, Li WL et al. Seasonal effect on disease onset and presentation in anti-MDA5 positive dermatomyositis. Front Med (Lausanne). 2022;9.","DOI":"10.3389\/fmed.2022.837024"},{"key":"3600_CR19","doi-asserted-by":"crossref","unstructured":"Toquet S, Granger B, Uzunhan Y, Mariampillai K, Nunes H, Benveniste O et al. The seasonality of dermatomyositis associated with anti-MDA5 antibody: an argument for a respiratory viral trigger. Autoimmun Rev. 2021;20(4).","DOI":"10.1016\/j.autrev.2021.102788"},{"key":"3600_CR20","doi-asserted-by":"crossref","unstructured":"Huang L, Zhu W, Ye Y, Wu X, Yan Q, Wang Z et al. Association of cytomegalovirus infection with anti-MDA5 antibody-positive dermatomyositis: a prospective cohort study. Front Med (Lausanne). 2021;8.","DOI":"10.3389\/fmed.2021.740154"},{"key":"3600_CR21","doi-asserted-by":"crossref","unstructured":"Huang L, Fu Q, Ye Y, Lin Y, Yan Q, Chen S. High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center. Arthritis Res Ther. 2021;23(1).","DOI":"10.1186\/s13075-021-02606-8"},{"key":"3600_CR22","doi-asserted-by":"crossref","unstructured":"Mammen AL, Allenbach Y, Stenzel W, Benveniste O. 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018. Neuromuscul Disord. 2020;30(1).","DOI":"10.1016\/j.nmd.2019.10.005"},{"key":"3600_CR23","doi-asserted-by":"crossref","unstructured":"Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford). 2004;43(1).","DOI":"10.1093\/rheumatology\/keg427"},{"key":"3600_CR24","doi-asserted-by":"crossref","unstructured":"Schaefer-Prokop C, Prokop M, Fleischmann D, Herold C. High-resolution CT of diffuse interstitial lung disease: key findings in common disorders. Eur Radiol. 2001;11(3).","DOI":"10.1007\/s003300000648"},{"key":"3600_CR25","doi-asserted-by":"crossref","unstructured":"Zuo Y, Ye L, Liu M, Li S, Liu W, Chen F et al. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology (Oxford). 2020;59(10).","DOI":"10.1093\/rheumatology\/keaa034"},{"key":"3600_CR26","doi-asserted-by":"crossref","unstructured":"Jin Q, Fu L, Yang H, Chen X, Lin S, Huang Z et al. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis. J Intern Med. 2023;293(4).","DOI":"10.1111\/joim.13607"},{"key":"3600_CR27","doi-asserted-by":"crossref","unstructured":"Folgori L, Tersigni C, Hsia Y, Kortsalioudaki C, Heath P, Sharland M et al. The relationship between Gram-negative colonization and bloodstream infections in neonates: a systematic review and meta-analysis. Clin Microbiol Infect. 2018;24(3).","DOI":"10.1016\/j.cmi.2017.08.008"},{"key":"3600_CR28","doi-asserted-by":"crossref","unstructured":"Roe K. A latent pathogen infection classification system that would significantly increase healthcare safety. Immunol Res. 2023;71(5).","DOI":"10.1007\/s12026-023-09377-1"},{"key":"3600_CR29","doi-asserted-by":"crossref","unstructured":"Morimoto AM, Flesher DT, Yang J, Wolslegel K, Wang X, Brady A et al. Association of endogenous anti-interferon-\u03b1 autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(8).","DOI":"10.1002\/art.30399"},{"key":"3600_CR30","doi-asserted-by":"crossref","unstructured":"Zhu Y, Wang L, Sun Y, Wang J, Lv C, You H et al. Serum Krebs von Den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease. Clin Exp Rheumatol. 2022;40(2).","DOI":"10.55563\/clinexprheumatol\/zmn18h"},{"key":"3600_CR31","unstructured":"Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J et al. Autoantibodies neutralizing type I IFNs are present in ~\u20094% of uninfected individuals over 70 years old and account for ~\u200920% of COVID-19 deaths. Sci Immunol. 2021;6(62)."},{"key":"3600_CR32","unstructured":"Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515)."},{"key":"3600_CR33","doi-asserted-by":"crossref","unstructured":"Wang G, Wang Q, Wang Y, Liu C, Wang L, Chen H et al. Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study. Front Immunol. 2021;12.","DOI":"10.3389\/fimmu.2021.791348"},{"key":"3600_CR34","doi-asserted-by":"crossref","unstructured":"David P, Sinha S, Iqbal K, De Marco G, Taheri S, McLaren E et al. MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C). EBioMedicine. 2024;104.","DOI":"10.1016\/j.ebiom.2024.105136"},{"key":"3600_CR35","doi-asserted-by":"crossref","unstructured":"He L, Ge Y, Li S, Huang K, Liu X, Chen F et al. Clinical role of bronchoalveolar lavage in dermatomyositis-associated interstitial lung disease. Rheumatology (Oxford). 2021;61(1).","DOI":"10.1093\/rheumatology\/keab586"},{"key":"3600_CR36","doi-asserted-by":"crossref","unstructured":"Teijaro JR. Type I interferons in viral control and immune regulation. Curr Opin Virol. 2016;16.","DOI":"10.1016\/j.coviro.2016.01.001"},{"key":"3600_CR37","doi-asserted-by":"crossref","unstructured":"Espinosa V, Dutta O, McElrath C, Du P, Chang YJ, Cicciarelli B et al. Type III interferon is a critical regulator of innate antifungal immunity. Sci Immunol. 2017;2(16).","DOI":"10.1126\/sciimmunol.aan5357"},{"key":"3600_CR38","doi-asserted-by":"crossref","unstructured":"Lauwerys BR, Ducreux J, Houssiau FA. Type I interferon blockade in systemic lupus erythematosus: where do we stand? Rheumatology (Oxford). 2014;53(8).","DOI":"10.1093\/rheumatology\/ket403"},{"key":"3600_CR39","doi-asserted-by":"crossref","unstructured":"Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381(3).","DOI":"10.1056\/NEJMc1900045"},{"key":"3600_CR40","doi-asserted-by":"crossref","unstructured":"Jiang Z, Yao X, Tang F, Ma W. Case report: successful treatment of anti-MDA5-positive to negative dermatomyositis-associated interstitial lung disease with the JAK inhibitor tofacitinib. Immun Inflamm Dis. 2023;11(6).","DOI":"10.1002\/iid3.897"},{"key":"3600_CR41","doi-asserted-by":"crossref","unstructured":"Wu W, Guo B, Sun W, Chen D, Xu W, Chen Z et al. Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multi-centre cohort study. Eur Respir J. 2025;65(5).","DOI":"10.1183\/13993003.01488-2024"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03600-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:37:04Z","timestamp":1751431024000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03600-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3600"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03600-0","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the China-Japan Friendship Hospital (2019-SDZL-3).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants signed an informed consent agreement.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}